Vimta Labs Limited — PPTs, 28-04-2025: Investor Presentation

**Financial Highlights:**

Vimta Labs reported a total income of ₹961 Mn for Q4 FY25, reflecting a YoY increase of 31.4%. The EBITDA for the quarter stood at ₹347 Mn with a margin of 36.1%, while profit before tax (PBT) was ₹250 Mn, up 39.5% YoY. For the full fiscal year FY25, total income reached ₹3,482 Mn, with a healthy EBITDA margin of 36.2%. The net profit (PAT) for FY25 was ₹668 Mn, an increase of 36.8% from FY24.

**Strategic Initiatives and Growth Drivers:**

Vimta has entered clinical trial services and successfully completed multiple regulatory audits, enhancing its operational credibility. Strategic relocations, such as moving the Pune food testing lab to Nashik, and expansion of its laboratory space further support its growth trajectory.

**Business Developments:**

The company merged EMTAC with Vimta, sanctioned by NCLT, alongside a successful business transfer of its CRL division to Thyrocare, consolidating its market position.

**Market Position and Competitive Advantage:**

Vimta ranks among the top CROs in India, with a strong focus on contract research across pharmaceutical, food, and environmental sectors, benefiting from a broad regulatory compliance framework.

**Investor Implications:**

Looking ahead, Vimta anticipates significant growth driven by escalating demand in its sectors and strategic expansions, presenting potential growth opportunities for investors.